Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
206.97
+1.82 (0.89%)
At close: Aug 10, 2026, 4:00 PM EDT
208.80
+1.83 (0.88%)
Pre-market: Aug 11, 2026, 7:43 AM EDT
Revolution Medicines Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 815.44 | 383.75 | 543.06 | 696.15 | 161.41 | 108.5 |
Short-Term Investments | 3,123 | 1,642 | 1,746 | 1,157 | 483.53 | 468.56 |
Cash & Short-Term Investments | 3,938 | 2,026 | 2,289 | 1,853 | 644.94 | 577.05 |
Cash Growth | 84.26% | -11.52% | 23.55% | 187.31% | 11.77% | 30.93% |
Accounts Receivable | - | - | - | 1.25 | 4.67 | 5.93 |
Other Current Assets | 90.37 | 49.36 | 38.33 | 25.07 | 10.57 | 6.79 |
Total Current Assets | 4,028 | 2,075 | 2,328 | 1,879 | 660.19 | 589.77 |
Net Property, Plant & Equipment | 162.45 | 165.28 | 141.82 | 100.01 | 73.74 | 71.24 |
Other Intangible Assets | 55.8 | 55.8 | 56.67 | 57.74 | 58.81 | 59.88 |
Goodwill | 14.61 | 14.61 | 14.61 | 14.61 | 14.61 | 14.61 |
Other Long-Term Assets | 62.07 | 43.79 | 17.57 | 10.06 | 4.59 | 2.5 |
Total Assets | 4,323 | 2,355 | 2,558 | 2,062 | 811.93 | 737.99 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 88.42 | 64.62 | 54.43 | 61.79 | 21.31 | 14.06 |
Accrued Expenses | 248.89 | 209.34 | 96.62 | 74.69 | 29.45 | 27.72 |
Current Portion of Leases | 16.75 | 16.47 | 12.87 | 7.37 | 6.77 | 6.21 |
Unearned Revenue | - | - | - | - | 4.46 | 12.36 |
Total Current Liabilities | 354.06 | 290.42 | 163.91 | 143.85 | 61.98 | 60.35 |
Long-Term Debt | 487.43 | - | - | - | - | - |
Long-Term Leases | 137.74 | 142.23 | 122.97 | 80.58 | 57.43 | 60.42 |
Other Long-Term Liabilities | 737.8 | 290.02 | 6.75 | 11.09 | 7.33 | 14.65 |
Total Long-Term Liabilities | 1,363 | 432.25 | 129.72 | 91.66 | 64.76 | 75.07 |
Total Liabilities | 1,717 | 723.21 | 293.1 | 235.51 | 126.74 | 135.42 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
Additional Paid-in Capital | 6,579 | 4,497 | 4,002 | 2,963 | 1,388 | 1,056 |
Accumulated Other Comprehensive Income | -5.95 | 3.24 | 1.32 | 0.54 | -1.78 | -0.38 |
Retained Earnings | -3,967 | -2,869 | -1,738 | -1,138 | -701.34 | -452.64 |
Shareholders' Equity | 2,606 | 1,631 | 2,265 | 1,826 | 685.19 | 602.57 |
Total Liabilities & Equity | 4,323 | 2,355 | 2,558 | 2,062 | 811.93 | 737.99 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 641.93 | 158.7 | 135.84 | 87.94 | 64.21 | 66.63 |
Net Cash (Debt) | 3,296 | 1,867 | 2,153 | 1,765 | 580.74 | 510.42 |
Net Cash Growth | 64.44% | -13.30% | 22.01% | 203.93% | 13.78% | 25.08% |
Net Cash Per Share | 16.59 | 9.82 | 12.84 | 15.60 | 7.20 | 7.01 |
Book Value | 2,606 | 1,631 | 2,265 | 1,826 | 685.19 | 602.57 |
Book Value Per Share | 13.11 | 8.58 | 13.50 | 16.14 | 8.50 | 8.28 |
Tangible Book Value | 2,536 | 1,561 | 2,194 | 1,754 | 611.77 | 528.08 |
Tangible Book Value Per Share | 12.76 | 8.21 | 13.08 | 15.50 | 7.59 | 7.25 |